ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0235

Fractures in Patients with Acute CPP Crystal Arthritis versus Matched Comparators in a Large Cohort Study
Abstract Number: 2339

Fragility of Randomized Clinical Trials of Systemic Lupus Erythematosus and Lupus Nephritis Therapies
Abstract Number: 1201

Frailty and Its Impact on Patient Reported Outcomes in Polymyalgia Rheumatica
Abstract Number: 2138

Frailty Is a Predictor of Incident Osteoporotic Fractures in Veterans with Rheumatoid Arthritis
Abstract Number: 1288

Frailty Is Associated with Higher Risk of Readmission in Patients with Rheumatoid Arthritis
Abstract Number: 2117

Frailty Is Associated with Mortality in Veterans with Rheumatoid Arthritis
Abstract Number: 0561

Frequency of Anti-Ro Antibodies in Systemic Lupus Erythematosus Patients: Insights from Multicenter and National Registry
Abstract Number: 2577

Frequency of Atherosclerotic Cardiovascular Disease Following a Diagnosis of Idiopathic Inflammatory Myopathy: Data from a Large National Registry
Abstract Number: 0822

From Biomarkers to Endotypes: Data-driven Identification of Knee Osteoarthritis Patients Subtypes
Abstract Number: 1960

From Clinical Amyopathy to Severe Oropharyngeal Dysphagia in Pure Dermatomyositis: A Greater Extent of Muscle Weakness Is Associated with a Higher Cancer Prevalence
Abstract Number: 2086

From Fellow to Fellowship Director: Gender Equity in Pediatric Rheumatology Pipeline
Abstract Number: 0328

From Patient Needs to Platform Design: Using Patient Preference to Guide the Development of a Post-Viral Fibromyalgia Management App
Abstract Number: 1139

From Skin to Bone Lesions: A Pioneer Study Unraveling the Underdiagnosis of SAPHO Syndrome in the Dominican Republic
Abstract Number: 0312

Frontal Lobe Activation and Gait Alterations During Single- and Dual-task Walking in People with Knee Osteoarthritis: A Functional Near-infrared Spectroscopy Study
Abstract Number: 2593

FT011 for the Treatment of Systemic Sclerosis. Results from a Phase II Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].